EFFORTS TO CURB ANTIMICROBIAL RESISTANCE (AMR) REQUIRE A MULTIFACETED APPROACH:

- Contributions to research and science
- Antimicrobial stewardship
- Responsible manufacturing
- Support for access efforts

RESPONSIBLE ANTIBIOTIC MANUFACTURING AND THE ENVIRONMENT

Antibiotics can end up in wastewaters through the discharge of emissions from antibiotic manufacturing, and in sufficient concentration, this may contribute to antimicrobial resistance.

The AMR Industry Alliance (AMRIA) mobilises the know-how, resources and infrastructure of industry in efforts to curb AMR:

1. Alliance members follow the Common Antibiotic Manufacturing Framework (CAMF) developed by AMRIA. CAMF sets out a risk assessment methodology and minimum requirements for meeting environmental standards.

2. Alliance members supported the development of science-driven antibiotic discharge targets, called Predicted No-Effect Concentrations (PNECs) for minimizing environmental impact.

3. Alliance members periodically assess delivery against CAMF and PNEC at manufacturing sites owned by the Alliance and at direct supplier sites.

The Framework, incorporating the PNECs, became the basis of the AMRIA Industry Antibiotic Manufacturing Standard in June 2022.

THE HIGHLIGHTS (Alliance member activities: 1 April 2021 - 31 March 2023)

**RESPONSIBLE MANUFACTURING AT SITES OWNED BY ALLIANCE MEMBERS**

- 95% of owned sites have been assessed against CAMF
- 90% of surveyed members with all owned sites either fully or partially met CAMF requirements
- 88% of products made at owned sites were assessed against PNEC targets
- 84% of assessed products made at owned sites met PNEC targets

**RESPONSIBLE MANUFACTURING AT DIRECT SUPPLIER MANUFACTURING SITES**

- 73% of supplier sites had CAMF conveyed to them by Alliance members
- 50% of supplier sites have been assessed against CAMF
- 56% of surveyed members with all supplier sites either fully or partially met CAMF requirements
- 53% of products made at supplier sites were assessed against PNEC targets
- 76% of assessed products made at supplier sites met PNEC targets

LOOKING TO THE FUTURE

- The introduction of the AMRIA Industry Antibiotic Manufacturing Standard
- The British Standards Institution’s (BSI’s) launch of an independent certification program to provide verification that an antibiotic is made in accordance with the industry standard

Building on sustained commitment to assess Alliance members’ own antibiotic manufacturing operations and those of their direct suppliers, the Alliance has also taken a major step to drive change across the global antibiotic supply chain with:

Looking to the future, these achievements are part of a strategy to ensure that antibiotic use will reduce the risk of resistance to antibiotics, helping to protect public health and the environment.

To read more about this work visit: www.amrindustryalliance.org/mediaroom/amr-industry-alliance-contributions-to-responsible-antibiotic-manufacturing

The AMR Industry Alliance is a coalition of 77 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and 10 trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. The AMR Industry Alliance will ensure that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap and will measure progress made in the fight against antimicrobial resistance.